Authors: Camilleri, M Chey, WY Mayer, EA Northcutt, AR Heath, A Dukes, GE McSorley, D Mangel, AM

Citation: M. Camilleri et al., A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome, ARCH IN MED, 161(14), 2001, pp. 1733-1740

Authors: Watson, ME Lacey, L Kong, S Northcutt, AR McSorley, D Hahn, B Mangel, AW

Citation: Me. Watson et al., Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome, AM J GASTRO, 96(2), 2001, pp. 455-459

Authors: Camilleri, M Northcutt, AR Kong, S Dukes, GE McSorley, D Mangel, AW

Citation: M. Camilleri et al., Efficacy and safety of alosetron in women with irritable bowel syndrome: arandomised, placebo-controlled trial, LANCET, 355(9209), 2000, pp. 1035-1040

Authors: Camilleri, M Mayer, EA Drossman, DA Heath, A Dukes, GE McSorley, D Kong, S Mangel, AW Northcutt, AR

Citation: M. Camilleri et al., Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist, ALIM PHARM, 13(9), 1999, pp. 1149-1159

Authors: Mangel, AW Northcutt, AR

Citation: Aw. Mangel et Ar. Northcutt, Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients, ALIM PHARM, 13, 1999, pp. 77-82

Authors: Hamm, LR Sorrells, SC Harding, JP Northcutt, AR Heath, AT Kapke, GF Hunt, CM Mangel, AW

Citation: Lr. Hamm et al., Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome Criteria, AM J GASTRO, 94(5), 1999, pp. 1279-1282